Background: Nonadherence to medication is a recognized problem and may be the most
challenging aspect of treatment. Methods: We performed a systematic review of factors that …

Psychiatric comorbidities are common among patients with schizophrenia. Substance abuse
comorbidity predominates. Anxiety and depressive symptoms are also very common …

The present article provides a narrative review of empirical studies on metacognitive training
in psychosis (MCT). MCT represents an amalgam of cognitive-behavioral therapy (CBT) …

About half or more of the patients with chronic psychiatric illnesses, either do not take their
medications correctly, or completely stop taking them. The problem of poor initial compliance …

Aims: To examine medication adherence and discontinuation in two separate groups of
patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Non-adherence is a major problem in the treatment of schizophrenia. Its high prevalence,
potentially severe consequences and associated costs make the study of this phenomenon …

Importance Cognitive interventions increasingly complement psychopharmacological
treatment to enhance symptomatic and functional outcome in schizophrenia. Metacognitive …

Metacognitive training (MCT) for patients with schizophrenia is a novel psychological group
treatment targeting cognitive biases putatively involved in the pathogenesis of schizophrenia …